Atossa Therapeutics (ATOS) announced data describing the discovery of compounds that may be synergistic with (Z)-endoxifen and that could potentially be used in combinations for the treatment of breast cancer. The data is being presented in a poster at the 2024 San Antonio Breast Cancer Symposium, SABCS, on December 13, 2024. The data suggest that combination therapies with (Z)-endoxifen and agents targeting topoisomerase, CDK, mTOR/PI3K and AKT have potential in the treatment of breast cancer but require further study.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATOS:
- Atossa Therapeutics announces full result from KARISMA-Endoxifen trial
- Atossa Therapeutics announces resuts from Phase 2 KARISMA-Endoxifen study
- Atossa Therapeutics announces three posters on Phase 2 EVANGELINE trial
- Atossa Therapeutics presents data from research investigating Z-Endoxifen
- Atossa Therapeutics announces five abstracts on Z-endoxifen
Questions or Comments about the article? Write to editor@tipranks.com